NTLA has been the topic of several other reports. Zacks Investment Research downgraded shares of Intellia Therapeutics from a buy rating to a hold rating in a report on Wednesday, July 10th. Wedbush upgraded shares of Intellia Therapeutics from a neutral rating to an outperform rating and raised their price objective for the stock from $20.00 to $21.00 in a research report on Friday, May 3rd. Chardan Capital restated a buy rating and set a $57.50 price objective on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. Roth Capital initiated coverage on shares of Intellia Therapeutics in a research report on Monday, June 10th. They set a neutral rating and a $16.00 price objective for the company. Finally, Evercore ISI initiated coverage on shares of Intellia Therapeutics in a research report on Thursday, April 11th. They set an outperform rating for the company. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $25.31.
NTLA traded down $0.48 during midday trading on Thursday, hitting $17.61. 539,821 shares of the company traded hands, compared to its average volume of 492,358. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.74 and a quick ratio of 7.74. The stock has a market cap of $804.95 million, a P/E ratio of -8.89 and a beta of 2.62. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $32.95. The stock’s 50 day moving average price is $16.29.
Several hedge funds and other institutional investors have recently bought and sold shares of NTLA. Nikko Asset Management Americas Inc. boosted its stake in shares of Intellia Therapeutics by 381.7% in the second quarter. Nikko Asset Management Americas Inc. now owns 5,161,098 shares of the company’s stock valued at $84,487,000 after purchasing an additional 4,089,744 shares during the period. ARK Investment Management LLC lifted its stake in Intellia Therapeutics by 17.3% in the first quarter. ARK Investment Management LLC now owns 7,981,198 shares of the company’s stock worth $136,319,000 after acquiring an additional 1,179,246 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Intellia Therapeutics by 111.8% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,216,660 shares of the company’s stock worth $36,287,000 after purchasing an additional 1,169,968 shares in the last quarter. Deutsche Bank AG raised its holdings in Intellia Therapeutics by 75.5% during the fourth quarter. Deutsche Bank AG now owns 635,956 shares of the company’s stock worth $8,680,000 after purchasing an additional 273,501 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Intellia Therapeutics by 502.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 260,259 shares of the company’s stock worth $3,552,000 after purchasing an additional 217,071 shares in the last quarter. 74.47% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Recommended Story: Trading Penny Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.